Wockhardt Limited (WOCKPHARMA) — Board Meeting | 10 August 2026 (3 announcements)

Wockhardt Limited held its 27th AGM on 10 August 2026, approving audited financial statements, appointing directors, sanctioning up to ₹1,000 Crore in related party transactions with Wockhardt Bio AG, CP Pharmaceuticals, and Wockhardt UK Limited, and authorizing capital raising of up to ₹3,000 Crore. Shareholders also approved executive remuneration and related party transaction ratifications with strong voting support. The meeting was conducted via video conferencing with 187 shareholders participating, including remote e-voting via NSDL and in-person e-voting. All key resolutions passed with over 95% approval, reflecting shareholder confidence in management continuity and capital plans.

Wockhardt Limited disclosed its Monitoring Agency Report for the QIP issue, confirming no deviation in utilization of proceeds for the quarter ended June 30, 2026. The report validates that all funds were used as per the offer document, with net proceeds revised to Rs 977.79 crores after lower-than-expected expenses. The Board and Audit Committee reviewed the report, and Crisil Ratings confirmed compliance with SEBI regulations. No material changes or forward guidance were provided in the filing.

Wockhardt Limited announced the outcome of its board meeting held on August 10, 2026, where it approved un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and independently reviewed by MSKC & Associates LLP, which confirmed no material misstatements. The filing includes detailed financial statements, notes on subsidiaries, and compliance with SEBI regulations. The company reaffirmed its focus on the pharmaceutical segment and disclosed earnings per share figures for both standalone and consolidated entities.